See more : J&T Global Express Ltd (1519.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Kringle Pharma, Inc. (4884.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kringle Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- KML Technology Group Limited (8065.HK) Income Statement Analysis – Financial Results
- Nanobiotix S.A. (NANO.PA) Income Statement Analysis – Financial Results
- Network18 Media & Investments Limited (NETWORK18.NS) Income Statement Analysis – Financial Results
- Timbercreek Financial Corp. (TBCRF) Income Statement Analysis – Financial Results
- MAAS Group Holdings Limited (MGH.AX) Income Statement Analysis – Financial Results
Kringle Pharma, Inc. (4884.T)
About Kringle Pharma, Inc.
Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 69.25M | 391.83M | 289.76M | 467.62M | 0.00 |
| Cost of Revenue | 0.00 | 88.41M | 71.60M | 0.00 | 0.00 |
| Gross Profit | 69.25M | 303.42M | 218.16M | 467.62M | 0.00 |
| Gross Profit Ratio | 100.00% | 77.44% | 75.29% | 100.00% | 0.00% |
| Research & Development | 716.00M | 533.00M | 398.00M | 489.00M | 265.80M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 196.00M | 178.00M | 150.00M | 105.95M |
| Other Expenses | 242.01M | 82.08M | 65.84M | 63.35M | 0.00 |
| Operating Expenses | 958.01M | 729.58M | 576.04M | 639.22M | 371.74M |
| Cost & Expenses | 958.01M | 817.99M | 647.64M | 639.22M | 371.74M |
| Interest Income | 0.00 | 207.00K | 1.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 6.61M | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 426.00M | -1.00K | 172.00M | 371.00M |
| EBITDA | -888.76M | 0.00 | -299.67M | 0.00 | 0.00 |
| EBITDA Ratio | -1,283.41% | -108.76% | -123.51% | -36.70% | 0.00% |
| Operating Income | -888.76M | -426.17M | -357.88M | -171.60M | -371.74M |
| Operating Income Ratio | -1,283.41% | -108.76% | -123.51% | -36.70% | 0.00% |
| Total Other Income/Expenses | 36.10M | 95.83M | 58.20M | 55.26M | 70.11M |
| Income Before Tax | -852.66M | -330.34M | -299.68M | -116.34M | -301.63M |
| Income Before Tax Ratio | -1,231.28% | -84.31% | -103.42% | -24.88% | 0.00% |
| Income Tax Expense | 1.49M | 1.49M | 1.49M | 1.49M | 420.00K |
| Net Income | -854.15M | -331.83M | -301.17M | -117.83M | -302.05M |
| Net Income Ratio | -1,233.43% | -84.69% | -103.94% | -25.20% | 0.00% |
| EPS | -158.46 | -68.33 | -72.51 | -106.70 | -71.45 |
| EPS Diluted | -158.46 | -68.33 | -72.51 | -106.70 | -71.45 |
| Weighted Avg Shares Out | 5.39M | 4.86M | 4.15M | 1.10M | 4.23M |
| Weighted Avg Shares Out (Dil) | 5.39M | 4.86M | 4.15M | 1.10M | 4.23M |
Source: https://incomestatements.info
Category: Stock Reports